vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Trade Desk (The) (TTD). Click either name above to swap in a different company.

Trade Desk (The) is the larger business by last-quarter revenue ($846.8M vs $487.7M, roughly 1.7× CLOVER HEALTH INVESTMENTS, CORP.). Trade Desk (The) runs the higher net margin — 22.1% vs -10.1%, a 32.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 14.3%). Trade Desk (The) produced more free cash flow last quarter ($285.3M vs $-69.0M). Over the past eight quarters, Trade Desk (The)'s revenue compounded faster (31.3% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

The Trade Desk, Inc. is an American multinational technology company that specializes in real-time programmatic marketing automation technologies, products, and services, designed to personalize digital content delivery to users.

CLOV vs TTD — Head-to-Head

Bigger by revenue
TTD
TTD
1.7× larger
TTD
$846.8M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+30.5% gap
CLOV
44.7%
14.3%
TTD
Higher net margin
TTD
TTD
32.2% more per $
TTD
22.1%
-10.1%
CLOV
More free cash flow
TTD
TTD
$354.2M more FCF
TTD
$285.3M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
TTD
TTD
Annualised
TTD
31.3%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
TTD
TTD
Revenue
$487.7M
$846.8M
Net Profit
$-49.3M
$186.9M
Gross Margin
80.7%
Operating Margin
-10.1%
30.3%
Net Margin
-10.1%
22.1%
Revenue YoY
44.7%
14.3%
Net Profit YoY
-123.2%
2.6%
EPS (diluted)
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
TTD
TTD
Q4 25
$487.7M
$846.8M
Q3 25
$496.6M
$739.4M
Q2 25
$477.6M
$694.0M
Q1 25
$462.3M
$616.0M
Q4 24
$337.0M
$741.0M
Q3 24
$331.0M
$628.0M
Q2 24
$356.3M
$584.5M
Q1 24
$346.9M
$491.3M
Net Profit
CLOV
CLOV
TTD
TTD
Q4 25
$-49.3M
$186.9M
Q3 25
$-24.4M
$115.5M
Q2 25
$-10.6M
$90.1M
Q1 25
$-1.3M
$50.7M
Q4 24
$-22.1M
$182.2M
Q3 24
$-9.2M
$94.2M
Q2 24
$7.4M
$85.0M
Q1 24
$-19.2M
$31.7M
Gross Margin
CLOV
CLOV
TTD
TTD
Q4 25
80.7%
Q3 25
78.1%
Q2 25
78.2%
Q1 25
76.8%
Q4 24
81.7%
Q3 24
24.5%
80.5%
Q2 24
30.3%
81.1%
Q1 24
23.6%
78.9%
Operating Margin
CLOV
CLOV
TTD
TTD
Q4 25
-10.1%
30.3%
Q3 25
-4.9%
21.8%
Q2 25
-2.2%
16.8%
Q1 25
-0.3%
8.8%
Q4 24
-6.4%
26.4%
Q3 24
-2.7%
17.3%
Q2 24
2.0%
16.2%
Q1 24
-6.5%
5.8%
Net Margin
CLOV
CLOV
TTD
TTD
Q4 25
-10.1%
22.1%
Q3 25
-4.9%
15.6%
Q2 25
-2.2%
13.0%
Q1 25
-0.3%
8.2%
Q4 24
-6.6%
24.6%
Q3 24
-2.8%
15.0%
Q2 24
2.1%
14.5%
Q1 24
-5.5%
6.4%
EPS (diluted)
CLOV
CLOV
TTD
TTD
Q4 25
$0.39
Q3 25
$0.23
Q2 25
$0.18
Q1 25
$0.10
Q4 24
$0.36
Q3 24
$0.19
Q2 24
$0.17
Q1 24
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
TTD
TTD
Cash + ST InvestmentsLiquidity on hand
$78.3M
$1.3B
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$2.5B
Total Assets
$541.0M
$6.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
TTD
TTD
Q4 25
$78.3M
$1.3B
Q3 25
$1.4B
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$194.5M
$1.9B
Q3 24
$288.0M
$1.7B
Q2 24
$254.8M
$1.5B
Q1 24
$208.3M
$1.4B
Stockholders' Equity
CLOV
CLOV
TTD
TTD
Q4 25
$308.7M
$2.5B
Q3 25
$340.9M
$2.6B
Q2 25
$344.2M
$2.7B
Q1 25
$336.1M
$2.7B
Q4 24
$341.1M
$2.9B
Q3 24
$342.2M
$2.6B
Q2 24
$324.9M
$2.4B
Q1 24
$292.5M
$2.2B
Total Assets
CLOV
CLOV
TTD
TTD
Q4 25
$541.0M
$6.2B
Q3 25
$559.7M
$5.9B
Q2 25
$575.0M
$6.0B
Q1 25
$583.7M
$5.7B
Q4 24
$580.7M
$6.1B
Q3 24
$653.0M
$5.5B
Q2 24
$674.2M
$5.2B
Q1 24
$671.8M
$4.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
TTD
TTD
Operating Cash FlowLast quarter
$-66.9M
$311.6M
Free Cash FlowOCF − Capex
$-69.0M
$285.3M
FCF MarginFCF / Revenue
-14.1%
33.7%
Capex IntensityCapex / Revenue
0.4%
3.1%
Cash ConversionOCF / Net Profit
1.67×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$795.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
TTD
TTD
Q4 25
$-66.9M
$311.6M
Q3 25
$12.1M
$224.7M
Q2 25
$5.4M
$165.0M
Q1 25
$-16.3M
$291.4M
Q4 24
$34.8M
$199.4M
Q3 24
$50.0M
$273.3M
Q2 24
$44.8M
$81.3M
Q1 24
$25.9M
$185.5M
Free Cash Flow
CLOV
CLOV
TTD
TTD
Q4 25
$-69.0M
$285.3M
Q3 25
$11.4M
$158.3M
Q2 25
$4.8M
$119.8M
Q1 25
$-16.5M
$232.3M
Q4 24
$33.3M
$179.2M
Q3 24
$49.6M
$224.6M
Q2 24
$44.4M
$59.1M
Q1 24
$25.5M
$178.2M
FCF Margin
CLOV
CLOV
TTD
TTD
Q4 25
-14.1%
33.7%
Q3 25
2.3%
21.4%
Q2 25
1.0%
17.3%
Q1 25
-3.6%
37.7%
Q4 24
9.9%
24.2%
Q3 24
15.0%
35.8%
Q2 24
12.5%
10.1%
Q1 24
7.3%
36.3%
Capex Intensity
CLOV
CLOV
TTD
TTD
Q4 25
0.4%
3.1%
Q3 25
0.1%
9.0%
Q2 25
0.1%
6.5%
Q1 25
0.0%
9.6%
Q4 24
0.5%
2.7%
Q3 24
0.1%
7.8%
Q2 24
0.1%
3.8%
Q1 24
0.1%
1.5%
Cash Conversion
CLOV
CLOV
TTD
TTD
Q4 25
1.67×
Q3 25
1.94×
Q2 25
1.83×
Q1 25
5.75×
Q4 24
1.09×
Q3 24
2.90×
Q2 24
6.04×
0.96×
Q1 24
5.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

TTD
TTD

Other$427.2M50%
Non Us$419.6M50%

Related Comparisons